New drug aims to stop breast cancer return in women with gene mutations
NCT ID NCT07353437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the drug fluzoparib to standard treatment after surgery can help prevent breast cancer from coming back in women with certain inherited gene mutations (HRR). About 334 women with early breast cancer will be randomly assigned to receive either fluzoparib plus standard care or standard care alone for one year. The study measures how long women remain free of invasive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluzoparib
- What this could lead to
- If successful, this could offer a new targeted treatment option to reduce the risk of breast cancer returning in people with specific genetic mutations.
- What could go wrong
- This is an early phase 2 trial, so results are not yet proven. The drug may cause side effects or not improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?